FDA cited Lovely Meds for misleading website claims that compounded semaglutide and tirzepatide are the same as FDA-approved drugs.
What happened
In August 2025, FDA reviewed the website lovelymeds.com and found it offers compounded semaglutide and tirzepatide products. FDA said the site’s claims “Same active ingredient as Wegovy and Ozempic” and “Same active ingredient as Zepbound & Mounjaro” are false or misleading because compounded drugs are not FDA-approved.
What FDA found
The website claim that compounded semaglutide has the “same active ingredient” as Wegovy and Ozempic is false or misleading, making the product misbranded (false or misleading labeling).
FDCA section 502(a) [21 U.S.C. § 352(a)]; section 502(bb) [21 U.S.C. § 352(bb)]The website claim that compounded tirzepatide has the “same active ingredient” as Zepbound and Mounjaro is false or misleading, making the product misbranded (false or misleading labeling).
FDCA section 502(a) [21 U.S.C. § 352(a)]; section 502(bb) [21 U.S.C. § 352(bb)]FDA says the misbranded drugs were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA says receiving misbranded drugs in interstate commerce, and delivering or offering to deliver them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Lovely Meds to take immediate action, including stopping the cited language, and to send a written response within 15 working days to CDER’s Office of Compounding Quality and Compliance describing steps taken, documentation, and how it will prevent recurrence. If it disagrees or cannot finish, it must explain why and give a timeline.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounders and pharmacies advertising GLP-1 products
- marketing and compliance teams for online pharmacies
This is a summary. Read the original letter on fda.gov.